



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Tuesday, November 24, 2009

# Receptron Incorporated

[View the current Receptron Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/8827-Receptron+Incorporated.html)  
(<http://www.bioportfolio.com/biocorporate/8827-Receptron+Incorporated.html>)

## Contact Details:

**835 Maude Avenue**  
**Mountain View**  
**CA**  
**94043-4021**  
**United States of America**

Tel: 415-988-9413  
Fax: 415-988-9415  
Email: [peptide@receptron.com](mailto:peptide@receptron.com)

Receptron has a novel and proprietary position in drug discovery and development. The company's original focus was on diabetes but now has expanded to include a diverse portfolio of research and development projects in the areas of endocrinology (growth hormone), hematology (EPO, TPO), and immunology. Receptron's proprietary technology also allows for future drug development in the cardiovascular and oncology areas.

Receptron's drug discovery technology and intellectual property is patent protected and is applied through research and development collaborations with some of the worlds leading pharmaceutical companies.

## Press Releases on Receptron Incorporated:

[Accuray Incorporated to Present at Piper Jaffray Healthcare Conference and J. P. Morgan Small/Mid Cap Conference](#)

23rd November, 2009

Accuray Incorporated

*SUNNYVALE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that its management is scheduled to present at -- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during*

[H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics](#)

20th November, 2009

Quest Diagnostics Incorporated

<a href="#">New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce. According to Quest Diagnostics Drug Testing Index(TM)</a>	20th November, 2009	Quest Diagnostics Incorporated	MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,
<a href="#">Spherix Announces the Closing of \$6.3 Million Registered Direct Offering</a>	19th November, 2009	Spherix Incorporated	BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting
<a href="#">Spherix Announces Results of Annual Shareholders Meeting</a>	19th November, 2009	Spherix Incorporated	-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods International In addition, Grant Thornton LLP was ratified as the Company's independent accountants

**Recepton Incorporated Patents:**



- 7037902- [Affinity small molecules for the EPO receptor](#)
- 6346390- [Receptor derived peptides involved in modulation of response to ligand binding](#)
- 6004758- [Receptor derived peptides involved in modulation of response to ligand binding](#)
- 5952293- [Receptor derived peptides involved in inhibition of receptor internalization in response to ligand binding](#)
- 5073540- [Composite binding site drugs](#)

**BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

